01 Rapid Increase in Adoption of Biosimilars for Cancer Treatment Oncology biosimilars are gaining broader acceptance as healthcare providers become more familiar with their clinical performance, regulatory standards, and potential economic benefits. Biosimilars for widely used cancer biologics are increasingly being incorporated into treatment pathways, particularly for therapies with established clinical experience and multiple approved alternatives. Greater physician confidence and institutional experience are helping biosimilars move from limited adoption toward a more significant role in routine oncology care. In March 2026, a JAMA study reported that biosimilar use among hospitals increased substantially between 2020 and 2024, reaching 93% of bevacizumab use, 87% of trastuzumab use, and 84% of rituximab use by 2024.
02 Expansion of Biosimilar Competition Across Major Oncology Biologics The oncology biosimilar landscape is expanding as additional manufacturers develop alternatives to high-value reference biologics used across cancer treatment. Increasing competition is providing healthcare systems with more purchasing options and encouraging manufacturers to compete through pricing, supply reliability, manufacturing capacity, and market access strategies. The expansion of biosimilar portfolios is also increasing the potential for competition across multiple oncology treatment categories. In November 2025, the U.S. Food and Drug Administration approved the first biosimilar to pertuzumab, with the product designated as interchangeable with the reference therapy, expanding biosimilar competition in breast cancer treatment.
01 Rising Pressure to Reduce Cancer Treatment Costs Supports Biosimilar Demand The high cost of biologic cancer therapies is encouraging healthcare providers, insurers, and patients to consider biosimilars as cost-efficient treatment alternatives. Greater use of biosimilars can increase competition among biologic products, reduce spending on selected therapies, and potentially allow healthcare resources to be redirected toward other areas of cancer care. As healthcare systems continue seeking ways to improve affordability without compromising treatment standards, the economic value of oncology biosimilars is strengthening their adoption.
01 Complex Reimbursement Structures Can Limit Biosimilar Adoption Reimbursement mechanisms can influence whether providers and healthcare institutions have sufficient financial incentives to select biosimilars over reference biologics. Differences between acquisition costs, reimbursement rates, payer policies, and site-of-care economics can create uneven incentives across hospitals and physician practices. These financial considerations can slow adoption even when biosimilars offer lower acquisition prices and comparable clinical performance.
01 Emergence of New Biosimilar Candidates Creates Opportunities Across High-Value Oncology Therapies The expiration or reduction of exclusivity barriers around widely used oncology biologics is creating opportunities for manufacturers to develop additional biosimilar products. High-value therapies with substantial treatment volumes can provide attractive opportunities for biosimilar developers seeking to expand oncology portfolios and healthcare systems seeking additional sources of competition. Increasing development activity can also broaden patient access to biologic-based cancer treatment by introducing additional products into established therapeutic categories.
01 Uneven Physician and Patient Confidence Can Slow Oncology Biosimilar Switching Although biosimilars are required to demonstrate high similarity to their reference products, differences in familiarity, clinical experience, and perceptions of treatment risk can influence prescribing and patient acceptance. Concerns may be particularly relevant when switching patients who are already receiving an established biologic therapy. Continued education, transparent clinical evidence, institutional protocols, and clear communication about biosimilar quality are therefore important for achieving consistent adoption across oncology settings.
June 2026 Amgen expanded its oncology biosimilar portfolio with continued commercialization of advanced biosimilar cancer therapies across global markets. The expansion strengthens access to lower-cost alternatives for biologic oncology treatments.
March 2026 Celltrion expanded its oncology biosimilar pipeline with regulatory submissions and commercialization activities for antibody-based cancer biosimilars. The company focused on increasing availability of cost-effective biologic treatments in key markets.
January 2026 Samsung Bioepis expanded its oncology biosimilar portfolio with additional launches and regulatory approvals across international markets. The company continued strengthening its position in antibody-based biosimilars for cancer treatment.
October 2025 Biocon Biologics expanded access to its oncology biosimilars through additional market launches and healthcare partnerships. The initiative supports wider availability of affordable targeted cancer therapies.